274 related articles for article (PubMed ID: 9393766)
1. Expression of multiple endocrine neoplasia 2B RET in neuroblastoma cells alters cell adhesion in vitro, enhances metastatic behavior in vivo, and activates Jun kinase.
Marshall GM; Peaston AE; Hocker JE; Smith SA; Hansford LM; Tobias V; Norris MD; Haber M; Smith DP; Lorenzo MJ; Ponder BA; Hancock JF
Cancer Res; 1997 Dec; 57(23):5399-405. PubMed ID: 9393766
[TBL] [Abstract][Full Text] [Related]
2. Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation.
Iwashita T; Asai N; Murakami H; Matsuyama M; Takahashi M
Oncogene; 1996 Feb; 12(3):481-7. PubMed ID: 8637703
[TBL] [Abstract][Full Text] [Related]
3. Absence of MEN2A- or 2B-type RET mutations in primary neuroblastoma tumour tissue.
Peaston AE; Camacho ML; Norris MD; Haber M; Marsh DJ; Robinson BG; Hyland VJ; Marshall GM
Mol Cell Probes; 1998 Aug; 12(4):239-42. PubMed ID: 9727201
[TBL] [Abstract][Full Text] [Related]
4. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.
Salvatore D; Melillo RM; Monaco C; Visconti R; Fenzi G; Vecchio G; Fusco A; Santoro M
Cancer Res; 2001 Feb; 61(4):1426-31. PubMed ID: 11245446
[TBL] [Abstract][Full Text] [Related]
5. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
Komminoth P
Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
[TBL] [Abstract][Full Text] [Related]
6. A potential pathogenetic mechanism for multiple endocrine neoplasia type 2 syndromes involves ret-induced impairment of terminal differentiation of neuroepithelial cells.
Califano D; D'Alessio A; Colucci-D'Amato GL; De Vita G; Monaco C; Santelli G; Di Fiore PP; Vecchio G; Fusco A; Santoro M; de Franciscis V
Proc Natl Acad Sci U S A; 1996 Jul; 93(15):7933-7. PubMed ID: 8755580
[TBL] [Abstract][Full Text] [Related]
7. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B.
Santoro M; Carlomagno F; Romano A; Bottaro DP; Dathan NA; Grieco M; Fusco A; Vecchio G; Matoskova B; Kraus MH
Science; 1995 Jan; 267(5196):381-3. PubMed ID: 7824936
[TBL] [Abstract][Full Text] [Related]
8. RET activation by germline MEN2A and MEN2B mutations.
Borrello MG; Smith DP; Pasini B; Bongarzone I; Greco A; Lorenzo MJ; Arighi E; Miranda C; Eng C; Alberti L
Oncogene; 1995 Dec; 11(11):2419-27. PubMed ID: 8570194
[TBL] [Abstract][Full Text] [Related]
9. Multiple endocrine neoplasia type 2B mutation in human RET oncogene induces medullary thyroid carcinoma in transgenic mice.
Acton DS; Velthuyzen D; Lips CJ; Höppener JW
Oncogene; 2000 Jun; 19(27):3121-5. PubMed ID: 10871866
[TBL] [Abstract][Full Text] [Related]
10. Characterization of ret oncogenic activation in MEN2 inherited cancer syndromes.
Xing S; Smanik PA; Oglesbee MJ; Trosko JE; Mazzaferri EL; Jhiang SM
Endocrinology; 1996 May; 137(5):1512-9. PubMed ID: 8612479
[TBL] [Abstract][Full Text] [Related]
11. Characterization of Ret-Shc-Grb2 complex induced by GDNF, MEN 2A, and MEN 2B mutations.
Ohiwa M; Murakami H; Iwashita T; Asai N; Iwata Y; Imai T; Funahashi H; Takagi H; Takahashi M
Biochem Biophys Res Commun; 1997 Aug; 237(3):747-51. PubMed ID: 9299438
[TBL] [Abstract][Full Text] [Related]
12. Characterization of gene expression induced by RET with MEN2A or MEN2B mutation.
Watanabe T; Ichihara M; Hashimoto M; Shimono K; Shimoyama Y; Nagasaka T; Murakumo Y; Murakami H; Sugiura H; Iwata H; Ishiguro N; Takahashi M
Am J Pathol; 2002 Jul; 161(1):249-56. PubMed ID: 12107109
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic RET receptors display different autophosphorylation sites and substrate binding specificities.
Liu X; Vega QC; Decker RA; Pandey A; Worby CA; Dixon JE
J Biol Chem; 1996 Mar; 271(10):5309-12. PubMed ID: 8621380
[TBL] [Abstract][Full Text] [Related]
14. Tissue-specific carcinogenesis in transgenic mice expressing the RET proto-oncogene with a multiple endocrine neoplasia type 2A mutation.
Kawai K; Iwashita T; Murakami H; Hiraiwa N; Yoshiki A; Kusakabe M; Ono K; Iida K; Nakayama A; Takahashi M
Cancer Res; 2000 Sep; 60(18):5254-60. PubMed ID: 11016655
[TBL] [Abstract][Full Text] [Related]
15. RET oligonucleotide microarray for the detection of RET mutations in multiple endocrine neoplasia type 2 syndromes.
Kim IJ; Kang HC; Park JH; Ku JL; Lee JS; Kwon HJ; Yoon KA; Heo SC; Yang HY; Cho BY; Kim SY; Oh SK; Youn YK; Park DJ; Lee MS; Lee KW; Park JG
Clin Cancer Res; 2002 Feb; 8(2):457-63. PubMed ID: 11839664
[TBL] [Abstract][Full Text] [Related]
16. Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes and Hirschsprung disease.
Smith DP; Eng C; Ponder BA
J Cell Sci Suppl; 1994; 18():43-9. PubMed ID: 7883791
[TBL] [Abstract][Full Text] [Related]
17. Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease.
Carlomagno F; Melillo RM; Visconti R; Salvatore G; De Vita G; Lupoli G; Yu Y; Jing S; Vecchio G; Fusco A; Santoro M
Endocrinology; 1998 Aug; 139(8):3613-9. PubMed ID: 9681515
[TBL] [Abstract][Full Text] [Related]
18. A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with shc adaptor proteins.
Asai N; Murakami H; Iwashita T; Takahashi M
J Biol Chem; 1996 Jul; 271(30):17644-9. PubMed ID: 8663426
[TBL] [Abstract][Full Text] [Related]
19. Full activation of MEN2B mutant RET by an additional MEN2A mutation or by ligand GDNF stimulation.
Bongarzone I; Vigano E; Alberti L; Borrello MG; Pasini B; Greco A; Mondellini P; Smith DP; Ponder BA; Romeo G; Pierotti MA
Oncogene; 1998 May; 16(18):2295-301. PubMed ID: 9620546
[TBL] [Abstract][Full Text] [Related]
20. Role of the RET proto-oncogene in sporadic hyperparathyroidism and in hyperparathyroidism of multiple endocrine neoplasia type 2.
Pausova Z; Soliman E; Amizuka N; Janicic N; Konrad EM; Arnold A; Goltzman D; Hendy GN
J Clin Endocrinol Metab; 1996 Jul; 81(7):2711-8. PubMed ID: 8675600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
